Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
San Francisco
California
94080
United States
Website: http://www.fiveprime.com/
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
246 articles about Five Prime Therapeutics, Inc.
-
FivePrime Therapeutics, Inc. CEO Done After Two Years, Rusty Williams Takes Over
8/18/2011
-
FivePrime Therapeutics, Inc. Provides an Update on Its Strategic Discovery Collaborations With Pfizer and GlaxoSmithKline
6/16/2011
-
Dyax Corp. and FivePrime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies
4/27/2011
-
FivePrime Therapeutics, Inc. to Present at Future Leaders in the Biotech Industry Conference in New York
4/7/2011
-
FivePrime Therapeutics, Inc. Nabs $495M Deal With Human Genome Sciences, Inc. to Develop Cancer Drug
3/17/2011
-
Five Prime Therapeutics, Inc. to Present at Cowen and Company 31st Annual Health Care Conference
2/28/2011
-
Five Prime Therapeutics, Inc. to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/10/2011
-
Five Prime Therapeutics, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11/9/2010
-
Five Prime Therapeutics, Inc. Announces Relocation to South San Francisco
10/19/2010
-
Five Prime Therapeutics, Inc. Elects Franklin Berger to Its Board of Directors
9/29/2010
-
Five Prime Therapeutics, Inc. to Present at Upcoming 9th Annual Biotechnology Industry Organization (BIO) Investor Forum
9/28/2010
-
Five Prime Therapeutics, Inc. Announces Issuance of Key Patents in the U.S. and Europe Covering Its Lead Oncology Drug
9/21/2010
-
FivePrime Therapeutics, Inc. and Fast Forward, LLC Collaborate to Speed New Treatments to People With Multiple Sclerosis
5/25/2010
-
Five Prime Therapeutics, Inc. to Present at the Biotechnology Industry Organization (BIO) International Convention
4/30/2010
-
Five Prime Therapeutics, Inc. to Present at Upcoming Investor Conferences
3/2/2010
-
Five Prime Therapeutics, Inc. Announces Milestone From Centocor Research And Development, Inc. for Therapeutic Program
2/24/2010
-
Five Prime Therapeutics, Inc. to Present at Lazard Capital Markets 6th Annual Healthcare Conference
11/11/2009
-
Five Prime Therapeutics, Inc. Adds Key Leaders to Its Management Team
10/16/2009
-
Company Profile for Five Prime Therapeutics, Inc.
10/16/2009
-
Five Prime Therapeutics, Inc. Appoints Julia Gregory Chief Executive Officer and Member of Board of Directors
6/9/2009